| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Dermatology,* the Center for Biochemistry, Medical Faculty, the Center for Molecular Medicine, the Institute of Medical Statistics, Informatics, and Epidemiology, and the Institute for Molecular and Cellular Sport Medicine,¶ University of Cologne, Cologne, Germany; the Department of Pathology,|| Vanderbilt University School of Medicine, Nashville, Tennessee; and the Veterans Administration Medical Center,** Nashville, Tennessee
Plasmin-catalyzed cleavage of the vascular endothelial growth factor (VEGF)-A isoform VEGF165 results in loss of its carboxyl-terminal heparin-binding domain and significant loss in its bioactivity. Little is known about the in vivo significance of this process. To investigate the biological relevance of the protease sensitivity of VEGF165 in wound healing we assessed the activity of a VEGF165 mutant resistant to plasmin proteolysis (VEGF165A111P) in a genetic mouse model of impaired wound healing (db/db mouse). In the present study we demonstrate that in this mouse model plasmin activity is increased at the wound site. The stability of the mutant VEGF165 was substantially increased in wound tissue lysates in comparison to wild-type VEGF165, thus indicating a prolonged activity of the plasmin-resistant VEGF165 mutant. The db/db delayed healing phenotype could be reversed by topical application of wild-type VEGF165 or VEGF165A111P. However, resistance of VEGF165 to plasmin cleavage resulted in the increased stability of vascular structures during the late phase of healing due to increased recruitment of perivascular cells and delayed and reduced endothelial cell apoptosis. Our data provide the first indication that plasmin-catalyzed cleavage regulates VEGF165-mediated angiogenesis in vivo. Inactivation of the plasmin cleavage site Arg110/Ala111 may preserve the biological function of VEGF165 in therapeutic angiogenesis under conditions in which proteases are highly active, such as wound repair and inflammation.
This article has been cited by other articles:
 |
|
 |
|
  J. Gutierrez, G. E. Konecny, K. Hong, A. Burges, T. D. Henry, P. D. Lambiase, W. Lee Wong, and Y. G. Meng A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF110 in Ovarian Cancer Tumors Clin. Chem., March 1, 2008; 54(3): 597 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mineur, A. C. Colige, Christophe. F. Deroanne, J. Dubail, F. Kesteloot, Y. Habraken, A. Noel, S. Voo, J. Waltenberger, C. M. Lapiere, et al. Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents J. Cell Biol., December 17, 2007; 179(6): 1261 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.R. Cesarone, G. Belcaro, S. Errichi, U. Cornelli, L. Pellegrini, I. Ruffini, B.M. Errichi, A. Ledda, G. Vinciguerra, A. Ricci, et al. Topical Heparin: New Observations Angiology, April 1, 2007; 58(1S): 16S - 20S. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Deshane, S. Chen, S. Caballero, A. Grochot-Przeczek, H. Was, S. Li Calzi, R. Lach, T. D. Hock, B. Chen, N. Hill-Kapturczak, et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism J. Exp. Med., March 19, 2007; 204(3): 605 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saaristo, T. Tammela, A. Farkkila, M. Karkkainen, E. Suominen, S. Yla-Herttuala, and K. Alitalo Vascular Endothelial Growth Factor-C Accelerates Diabetic Wound Healing Am. J. Pathol., September 1, 2006; 169(3): 1080 - 1087. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
